Sangui Biotech International, Inc. Stock Other OTC
Equities
SGBI
US80105B1017
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 65.58K | Sales 2022 | 69.19K | Capitalization | 3.09M |
---|---|---|---|---|---|
Net income 2021 | - | Net income 2022 | - | EV / Sales 2021 | 90.6 x |
Net Debt 2021 | 790K | Net Debt 2022 | 795K | EV / Sales 2022 | 56.1 x |
P/E ratio 2021 |
-25.6
x | P/E ratio 2022 |
-51.8
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 86.94% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Striepe
CEO | Chief Executive Officer | 62 | 05-02-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Striepe
CEO | Chief Executive Officer | 62 | 05-02-06 |
Hubertus Schmelz
BRD | Director/Board Member | 68 | 08-12-17 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |